1. Home
  2. companies
  3. Lantus

Lantus

Sanofi's new Lantus may not be the new Lantus
Sanofi's new Lantus may not be the new Lantus
Medical Marketing and Media
Sanofi
diabetes
Toujeo
Lantus
FDA OKs Sanofi's Toujeo. Will a diabetes drug price war follow?
FDA OKs Sanofi's Toujeo. Will a diabetes drug price war follow?
Fierce Biotech
Sanofi
diabetes
Toujeo
drug pricing
Lantus
Tresiba
Novo Nordisk
Lilly peglispro delay may be boon for its biosimilar
Lilly peglispro delay may be boon for its biosimilar
Medical Marketing and Media
Eli Lilly
Peglispro
diabetes
basal insulin
biosimilars
Sanofi
Lantus
FirstWord Lists – The best selling drugs in 2014
FirstWord Lists – The best selling drugs in 2014
First Word Pharma
Humira
Sovaldi
Remicade
Enbrel
Lantus
Rituxan
Advair
Avastin
Herceptin
Januvia
Merck
AbbVie
Gilead Sciences
JNJ
Amgen
Pfizer
Sanofi
Roche
GSK
The top 10 patent losses of 2015
The top 10 patent losses of 2015
Fierce Pharma
patents
Lantus
Abilify
Copaxone
Neulasta
Tracleer
Namenda
Avodart
Jalyn
Zyvox
Androgel
Synagis
Sanofi
Bristol-Myers Squibb
Otsuka
Teva Pharmaceutical
Amgen
Actelion
Actavis
GSK
Pfizer
AbbVie
AstraZeneca
Digesting Sanofi's Two Pieces Of News- Lantus' Challenging Outlook And The CEO Dismissal
Digesting Sanofi's Two Pieces Of News- Lantus' Challenging Outlook And The CEO Dismissal
Seeking Alpha
Sanofi
Lantus
Chris Viehbacher
Sanofi shares plunge after diabetes drug warning
Sanofi shares plunge after diabetes drug warning
Yahoo/AP
Sanofi
diabetes
Lantus
Sanofi And Novo Nordisk‘s Basal-Insulin Battle Continues
Sanofi And Novo Nordisk‘s Basal-Insulin Battle Continues
Bidness Etc.
Sanofi
Novo Nordisk
basal insulin
diabetes
Lantus
Levemir
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
Bidness Etc.
Sanofi
Novo Nordisk
diabetes
insulin
Lantus
Tresiba
Toujeo
Who's Winning The Insulin Showdown?
Who's Winning The Insulin Showdown?
Bidness Etc.
insulin
diabetes
Eli Lilly
Sanofi
Lantus
Peglispro
Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown
Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown
Fierce Biotech
Eli Lilly
Sanofi
Lantus
diabetes
basal insulin peglispro
Sanofi sues Eli Lilly over insulin rival to Lantus
Sanofi sues Eli Lilly over insulin rival to Lantus
Yahoo/Reuters
Sanofi
Eli Lilly
Lantus
diabetes
insulin
Lilly Wins EU Backing for Generic of Sanofi’s Lantus
Lilly Wins EU Backing for Generic of Sanofi’s Lantus
Bloomberg
Europe
generics
Eli Lilly
Sanofi
Lantus
diabetes
New rivals to top diabetes drug Lantus show promise in studies
New rivals to top diabetes drug Lantus show promise in studies
Yahoo/Reuters
diabetes
Lantus
insulin
Sanofi
Toujeo
Eli Lilly
Lilly's diabetes drug as effective as Sanofi's in late-stage trials
Lilly's diabetes drug as effective as Sanofi's in late-stage trials
Yahoo/Reuters
Eli Lilly
Sanofi
diabetes
basal insulin peglispro
Lantus
10 big brands keep pumping out big bucks, with a little help from price hikes
10 big brands keep pumping out big bucks, with a little help from price hikes
Fierce Pharma Marketing
Xyrem
Jazz Pharmaceuticals
Humulin
Eli Lilly
Premarin
Mylan
Lunesta
Sunovion
Benicar
Daiichi Sankyo
Lantus
Sanofi
Viagra
Pfizer
Gleevec
Novartis
Copaxone
Teva Pharmaceuticals
EpiPen
drug pricing
The 10 best-selling drugs of 2013
The 10 best-selling drugs of 2013
Fierce Pharma
Seretide
Rituxan
Remicade
MabThera
Lantus
Humira
Herceptin
Enbrel
Crestor
Avastin
Advair
Abilify
Novo Nordisk sees chance of U.S. Tresiba launch before rival products
Novo Nordisk sees chance of U.S. Tresiba launch before rival products
Yahoo/Reuters
Novo Nordisk
insulin
diabetes
Tresiba
Lantus
Sanofi
Eli Lilly
Merck joins race to copy Sanofi's diabetes drug Lantus
Merck joins race to copy Sanofi's diabetes drug Lantus
Yahoo/Reuters
Lantus
diabetes
Sanofi
Merck
Sanofi sues Eli Lilly over patents for top-selling insulin drug
Sanofi sues Eli Lilly over patents for top-selling insulin drug
Yahoo/Reuters
Sanofi
Eli Lilly
insulin
diabetes
Lantus

Click here to subscribe to daily news headlines in your email inbox